Want to join the conversation?
$GILD said that non-GAAP product GM was 87.2% for 1Q16 vs. 90.9% in 1Q15. The dip in GM reflects a $200MM charge or $0.12 EPS related to the jury verdict in the Merck trial in March. The company posted non-GAAP R&D expenses of $769MM, a rise of 18% vs. 1Q15 due to the continued progression of clinical studies.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.